Leonard Zehr, Author at BioTuesdays

Developments

Dipexium gets SME designation in Europe

Dipexium Pharmaceuticals (NASDAQ:DPRX) has been granted small and medium enterprise (SME) designation by the European Medicines Agency (EMA). The company recently completed its pivotal Phase 3 clinical trials...

October 4, 2016

Feature

Mesoblast developing multiple cell-based products

By Len Zehr Mesoblast (NASDAQ:MESO; ASX:MSB) has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of...

October 4, 2016

Developments

Aurinia posts positive Phase 2b voclosporin results

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin achieved its primary endpoint of complete remission (CR) at 24 weeks in a Phase 2b trial. In addition, when both doses of voclosporin were added to the current...

September 30, 2016

Executive Moves

Jason Flowerday named CEO of 3D Signatures

3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board."Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive...

September 27, 2016

Executive Moves

Stereotaxis strengthens financial position, expands Board of Directors

Stereotaxis (NASDAQ:STXS) has signed definitive agreements for multiple transactions that significantly strengthen its financial position and help accelerate and enhance its strategic market growth initiatives.The...

September 27, 2016

Developments

FDA grants orphan drug status to Soricimed’s SOR-C13

The FDA has granted orphan drug designation to closely-held Soricimed Biopharma’s peptide, SOR-C13, for the treatment of pancreatic cancer, following a similar designation for ovarian cancer In a statement, Paul Gunn...

September 27, 2016

Developments

Profound Medical treats first patient in TACT pivotal trial

The first patient has been treated in Profound Medical’s (TSX-V:PRN) TACT pivotal trial at Vanderbilt University Medical Center in Nashville, TN. TACT is a prospective, single-arm pivotal clinical study of 110 patients...

September 22, 2016

Feature

Knight Therapeutics “to get real” as it builds its commercial operations

By Len Zehr In the more than 30 months since its startup, Knight Therapeutics (TSX:GUD) has shown an uncanny knack for raising equity at increasing valuations, building a portfolio of some 20 innovative products for its...

September 20, 2016

Markets

Roth starts Recro Pharma at buy

Roth Capital Partners has launched coverage of Recro Pharma (NASDAQ:REPH) with a “buy” rating and a $24 price target. The stock closed at $9.31 on Thursday. “The impetus for our buy rating on Recro shares is the upside...

September 16, 2016

Markets

Scotiabank starts Novadaq at sector outperform

Scotiabank initiated coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “sector outperform” rating and a one-year price target of $18. The stock closed at $11.43 on Tuesday. Analyst Alan Ridgeway writes...

September 14, 2016

Author - Leonard Zehr

Dipexium gets SME designation in Europe

Mesoblast developing multiple cell-based products

Aurinia posts positive Phase 2b voclosporin results

Jason Flowerday named CEO of 3D Signatures

Stereotaxis strengthens financial position, expands Board of Directors

FDA grants orphan drug status to Soricimed’s SOR-C13

Profound Medical treats first patient in TACT pivotal trial

Knight Therapeutics “to get real” as it builds its commercial operations

Roth starts Recro Pharma at buy

Scotiabank starts Novadaq at sector outperform

Subscribe